Technical Analysis for BVNKF - Bavarian Nordic A/S

Grade Last Price % Change Price Change
grade D 25.2 -0.20% -0.0500
BVNKF closed down 0.2 percent on Tuesday, January 7, 2020, on 1.75 times normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Down Up
Historical BVNKF trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
MACD Bullish Signal Line Cross Bullish -0.20%
Pocket Pivot Bullish Swing Setup -0.20%
Volume Surge Other -0.20%
Narrow Range Bar Range Contraction -0.20%
Wide Bands Range Expansion -0.20%
Gapped Up Strength -0.20%
Narrow Range Bar Range Contraction 12.00%
Older signals for BVNKF ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus. In addition, the company is developing PROSTVAC, which is in Phase III clinical development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer; CV301 that is in Phase II clinical trial for the treatment multiple cancers; and MVA-BN Brachyury that has completed Phase I clinical trial for the treatment of metastatic cancer. The company has collaboration agreements with National Cancer Institute; Bristol-Myers Squibb; Janssen Pharmaceuticals, Inc.; Biomedical Advanced Research and Development Authority; US Department of Defense; and PCI Biotech. The company operates in the United States, Holland, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is headquartered in Kvistgård, Denmark.
Biotechnology Cancer Clinical Medicine Drugs Life Sciences Infectious Diseases Vaccines Bristol Myers Squibb Metastatic Cancer Cancer Vaccines Ebola Hpv National Cancer Institute Bavarian Nordic Ebola Vaccine Biomedical Advanced Research And Development Authority Company Markets Non Replicating Smallpox Cv301 Minimally Symptomatic Metastatic Castration Resistant Prostate Cancer Prostvac Treatment Multiple Cancers Treatment Of Life Threatening Infectious Diseases Treatment Of Metastatic Cancer Us Department Of Defense

Is BVNKF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 70.86
52 Week Low 19.2
Average Volume 570
200-Day Moving Average 0.0000
50-Day Moving Average 39.2309
20-Day Moving Average 27.6428
10-Day Moving Average 23.2960
Average True Range 1.7961
ADX 36.18
+DI 39.6405
-DI 59.2475
Chandelier Exit (Long, 3 ATRs ) 35.3480
Chandelier Exit (Short, 3 ATRs ) 24.5883
Upper Bollinger Band 38.7591
Lower Bollinger Band 16.5265
Percent B (%b) 0.39
BandWidth 80.4282
MACD Line -4.4933
MACD Signal Line -4.9361
MACD Histogram 0.4428
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.2000
Resistance 3 (R3) 25.2000 25.2000 25.2000
Resistance 2 (R2) 25.2000 25.2000 25.2000 25.2000
Resistance 1 (R1) 25.2000 25.2000 25.2000 25.2000 25.2000
Pivot Point 25.2000 25.2000 25.2000 25.2000 25.2000
Support 1 (S1) 25.2000 25.2000 25.2000 25.2000 25.2000
Support 2 (S2) 25.2000 25.2000 25.2000 25.2000
Support 3 (S3) 25.2000 25.2000 25.2000
Support 4 (S4) 25.2000